|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2000-8-30
|
|
pubmed:abstractText |
The first clinical studies of paclitaxel as a single agent for the treatment of relapsed or refractory low or intermediate grade non-Hodgkin's lymphomas (NHL) yielded controversial results regarding the response rates observed, mainly related to the dose and schedule of administration used. To obtain additional data concerning the efficacy and toxicity of paclitaxel in intermediate and high grade NHL we initiated a phase II study using a 3-hour infusion of high doses of paclitaxel.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
pubmed-author:BlayJ YJY,
pubmed-author:BouabdallahKK,
pubmed-author:CaillotDD,
pubmed-author:CasasnovasR ORO,
pubmed-author:DumontetCC,
pubmed-author:GabarroPP,
pubmed-author:GisselbrechtCC,
pubmed-author:HaiounCC,
pubmed-author:LederlinPP,
pubmed-author:MorelPP,
pubmed-author:QuesnelBB,
pubmed-author:RichardBB,
pubmed-author:StamatoullasAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
502-7
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10800167-Adolescent,
pubmed-meshheading:10800167-Adult,
pubmed-meshheading:10800167-Aged,
pubmed-meshheading:10800167-Agranulocytosis,
pubmed-meshheading:10800167-Anemia,
pubmed-meshheading:10800167-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10800167-Disease-Free Survival,
pubmed-meshheading:10800167-Drug Evaluation,
pubmed-meshheading:10800167-Female,
pubmed-meshheading:10800167-Hemorrhage,
pubmed-meshheading:10800167-Humans,
pubmed-meshheading:10800167-Infection,
pubmed-meshheading:10800167-Infusions, Intravenous,
pubmed-meshheading:10800167-Lymphoma, Non-Hodgkin,
pubmed-meshheading:10800167-Male,
pubmed-meshheading:10800167-Middle Aged,
pubmed-meshheading:10800167-Paclitaxel,
pubmed-meshheading:10800167-Recurrence,
pubmed-meshheading:10800167-Survival Rate,
pubmed-meshheading:10800167-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
|
|
pubmed:affiliation |
Hématologie Clinique, Hôpital Le Bocage CHU Dijon, 2104 Dijon Cedex, France. hemato.clinique@planetb.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
